/
ACTU
$1.58-$0.10 (-5.95%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$40.2M
24M shares
52-week range
$1.47 – $9.22
1% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
3.52%
Moderate
Price (6 mo)
Loading chart…
Change$-7.03
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| Gross margin | — | — | — | — |
| R&D | $16.4M | $21.7M | $18.7M | $10.3M |
| Operating income | −$20.2M | −$25.0M | −$25.2M | −$22.5M |
| EBITDA | −$20.1M | −$24.4M | −$25.2M | −$22.2M |
| Net income | −$20.2M | −$24.7M | −$27.3M | −$22.2M |
| Net margin | — | — | — | — |
| EPS (diluted) | -1.34 | -1.65 | -3.26 | -1.06 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $0 | $-0.80 | $-0.82–$-0.78 | 2 |
| 2027 | $6M | $-0.85 | $-0.93–$-0.77 | 3 |
| 2028 | $33M | $-0.93 | $-0.93–$-0.93 | 1 |
| 2029 | $68M | $-0.64 | $-0.64–$-0.64 | 1 |
Forward consensus · source: Financial Modeling Prep
DCF fair valuemodel estimate
Intrinsic value
$0.54
Price
$1.58
Implied downside
-66%
Peer comparison
Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
www.actuatetherapeutics.com- Employees
- 12
- IPO / List date
- Aug 13, 2024
- HQ
- FORT WORTH, TX
Held by traders on TradeandTell
No one on the platform currently holds ACTU.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ACTU as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ACTU yet.
